Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Zoetis Inc. (NYSE:ZTS)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on April 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of SS&C Technologies (NASDAQ:SSNC) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Wayfair (NYSE:W) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Sensata Technologies (NYSE:ST) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 5/1/2026.

Zoetis Stock Performance

Zoetis stock traded up $0.25 during midday trading on Tuesday, hitting $76.92. The stock had a trading volume of 18,097,939 shares, compared to its average volume of 4,877,302. The firm’s fifty day moving average is $116.50 and its two-hundred day moving average is $122.77. The company has a market capitalization of $32.25 billion, a PE ratio of 12.76, a P/E/G ratio of 1.29 and a beta of 0.87. Zoetis Inc. has a 52-week low of $75.11 and a 52-week high of $172.23. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.96 EPS for the current year.

Institutional Investors Weigh In On Zoetis

Large investors have recently added to or reduced their stakes in the stock. Global Wealth Strategies & Associates bought a new position in Zoetis during the 4th quarter worth about $25,000. Prosperity Bancshares Inc bought a new stake in shares of Zoetis in the 4th quarter valued at about $25,000. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the 1st quarter valued at $28,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis in the 4th quarter valued at $30,000. Finally, Root Financial Partners LLC increased its holdings in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZTS. Bank of America increased their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. JPMorgan Chase & Co. lowered their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday. Citigroup started coverage on Zoetis in a research report on Wednesday, April 15th. They set a “buy” rating and a $145.00 target price for the company. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, UBS Group lowered their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $141.25.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.